OTC · Biotechnology

Biotron Limited (BITRF) Stock

$0.04 +0.00% OTC: BITRF Healthcare

Biotron Limited is an Australian biotechnology firm focused on the development and market introduction of small-molecule compounds designed to combat various viral infections. The company's primary antiviral agent, BIT225, is currently undergoing Phase II clinical trials to assess its efficacy against SARS-CoV-2, HIV-1, and hepatitis C virus infections.

Valuation

MetricValue
Price$0.04
Market Cap$37.63M
P/E Ratio-6.67
P/B Ratio1.11
P/S Ratio-3785.25
EPS (TTM)$0.00
52-Week High$0.10
52-Week Low$0.00
Dividend Yield—

Financials & Margins

MetricValue
ROE-119.12%
ROA-50.16%
ROCE-71.46%
Gross Margin190.21%
Operating Margin—
Net Margin—
Debt/Equity0.00
Current Ratio1.47

Annual Financials (USD)

Metric20212022202320242025
Revenue$1.0M$2.0M$1.0M$2.0M$2.0M
Operating Profit$-3.0M$-3.0M$-4.0M$-4.0M$0
Net Profit$-3.0M$-3.0M$-3.0M$-3.0M$0
EPS$0.00$0.00$0.00$0.00$0.00
Op Margin-218.4%-178.1%-252.1%-213.1%-18.7%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$4.0M$2.0M$4.0M$0$1.0M
Total Liabilities$0$1.0M$1.0M$1.0M$0
Cash$4.0M$2.0M$4.0M$0$1.0M
Borrowings$0$0$0$0$0

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-3.0M$-2.0M$-3.0M$-4.0M$-1.0M
Investing Cash Flow$0$0$0$0$0
Financing Cash Flow$0$0$0$0$1.0M
Net Cash Flow$-3.0M$-2.0M$2.0M$-4.0M$1.0M
Free Cash Flow$-3.0M$-2.0M$-3.0M$-4.0M$-1.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-0.07
EV / EBITDA—
FCF Yield-2.66%
Quick Ratio1.47
Interest Coverage—
Return 1Y—
Return 3Y—
Return 5Y—

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
BNGIBangi Inc. $0.00 — — $525 0.00%
BPTSYBiophytis S.A. $0.25 +0.00% -0.02 $105224 0.00%
DYNTDynatronics Corporation $0.04 +0.00% -0.04 $403612 0.00%
GRCUGlobal Roundtable Corporation $0.00 — 0.00 $722675 0.00%
MCETMultiCell Technologies, Inc. $0.00 — — $50009 0.00%

About Biotron Limited

Biotron Limited is an Australian biotechnology firm focused on the development and market introduction of small-molecule compounds designed to combat various viral infections. The company's primary antiviral agent, BIT225, is currently undergoing Phase II clinical trials to assess its efficacy against SARS-CoV-2, HIV-1, and hepatitis C virus infections. Founded in 1999, Biotron Limited's main offices are situated in Sydney, Australia.

Biotron Limited is headquartered in AU.

Biotron Limited (BITRF) stock trades at $0.04 with a market capitalization of $37.63M. The stock is valued at a price-to-earnings (P/E) ratio of -6.67, price-to-book of 1.11, price-to-sales of -3785.25. Over the past 52 weeks the stock has ranged between $0.00 and $0.10, and currently trades 60.0% below its 52-week high.

On profitability, Biotron Limited generates a return on equity (ROE) of -119.12%, return on capital employed of -71.46%.

Official website: www.biotron.com.au

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides